PathomIQ

Executive Summary

PathomIQ is a privately held diagnostics company based in San Francisco, founded in 2019. The company has developed an AI platform that uniquely integrates morphological and genomic data to predict treatment response, while providing clear visual insights into the underlying biological mechanisms. This approach aims to address a critical gap in precision medicine—moving beyond static biomarkers to a dynamic, interpretable model of how a patient’s tumor will respond to specific therapies. PathomIQ’s technology could have broad applications in oncology and other complex diseases, enabling more personalized treatment decisions and improving patient outcomes. Although the company operates in a competitive landscape with other AI-driven diagnostics players, its focus on combining multiple data modalities and delivering mechanistic explanations differentiates it. PathomIQ is still in a relatively early stage, with no disclosed funding rounds or revenue. Key challenges will include validating the platform in clinical studies, securing strategic partnerships for data access and commercialization, and navigating regulatory pathways. Given the increasing demand for explainable AI in healthcare and the growing adoption of multi-omics approaches, PathomIQ is well-positioned to capture value if it can execute on its vision.

Upcoming Catalysts (preview)

• Q3 2026Announcement of a Strategic Partnership with a Major Cancer Center40% success
• Q4 2026Publication of Proof-of-Concept Study in a Peer-Reviewed Journal60% success
• Q1 2027Completion of a Seed or Series A Funding Round50% success